CardioVascular Disease Progression and Prognosis in COVID-19
Launched by UNIVERSITY OF BOLOGNA · Oct 27, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The CardioVascular Disease Progression and Prognosis in COVID-19 study is looking to understand how COVID-19 affects heart and lung health in patients. Researchers are focusing on adults who have been hospitalized due to worsening COVID-19 symptoms to find out what factors might predict the progression of cardiovascular disease and the risk of death. This study is not testing any new treatments but is gathering information about patients' medical histories, treatments received, and health outcomes to see how these relate to their COVID-19 experience.
To be eligible for this study, participants must be hospitalized for COVID-19 and be 18 years or older. Those who join the study can expect to provide information about their health and receive standard care for COVID-19. The goal is to help doctors better understand how to care for patients with COVID-19 and its effects on the heart and lungs, ultimately improving treatment and outcomes for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • hospitalization for COVID-19
- Exclusion Criteria:
- • age \<18 years
About University Of Bologna
The University of Bologna, one of the oldest and most prestigious academic institutions in the world, is dedicated to advancing knowledge and innovation in the field of healthcare through rigorous clinical research. With a strong emphasis on interdisciplinary collaboration and cutting-edge methodologies, the university sponsors a diverse range of clinical trials aimed at enhancing patient outcomes and contributing to the scientific community. Its commitment to ethical standards and regulatory compliance ensures that all trials are conducted with the utmost integrity, fostering an environment of trust and excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Olivia Manfrini, MD
Principal Investigator
DIMEC, Università di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials